Business
Valeant Pharmaceuticals makes hostile bid for Cephalon
March 29, 2011
Cephalon Inc. ended a joint venture for marketing two of its drugs after analysts raised questions about accounting practices involving the partnership in the wake of Enron Corp.’
April 2, 2002
Teva Pharmaceutical offers $6.8 billion for Cephalon
May 3, 2011
Cephalon Inc., which makes neurological drugs, agreed to buy French drug maker Group Lafon for $450 million in cash.
Dec. 4, 2001
Science & Medicine
Probably nothing is more heartbreaking for people who suffer from debilitating diseases than to hear of a promising new drug or treatment long before its efficacy has been conclusively proven.
June 25, 1995
Cephalon Inc., maker of the anti-drowsiness drug Provigil, said it received a subpoena from prosecutors in Philadelphia for documents relating to sales and marketing practices since 1998.
Sept. 8, 2004
Patients with Lou Gehrig’s disease should be allowed to take a free experimental drug that promises to slow, but not stop, their relentless paralysis, government advisors recommended Friday.
June 8, 1996
Cephalon Inc. and Chiron Corp. are talking with the Food and Drug Administration as it nears a decision on whether they can market their Lou Gehrig’s disease treatment, Myotrophin, in the U.S.
April 29, 1998
Pharmaceuticals: Despite restrictions, Cephalon’s modafinil may be sought after by many suffering from common fatigue.
Dec. 29, 1998
California-based researchers reported Monday that a new drug slows the neurological decline of patients with amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease, but a prominent specialist raised questions about the work’s validity.
June 13, 1995